Search

Search Constraints

You searched for: Author/Creator Savage, Mary

Search Results

1. Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. (June 2019)

2. O1–11–02: Kinetics of CNS APP metabolites in the presence of a BACE1 inhibitor in a non‐human primate model. (1st July 2013)

4. P1–361: Improved interpretation of amyloid tracer kinetic data through model‐based analysis. (1st July 2013)

5. P3‐073: Intervention of TAU Pathology Prevents Behavioral Changes in RTG4510 Mouse Model of Tauopathy. (1st July 2016)

6. P4‐036: Pharmacokinetics and Pharmacodynamics to Support Clinical Studies of MK‐8719: an O‐Glcnacase Inhibitor for Progressive Supranuclear Palsy. (1st July 2016)

7. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Issue 10318 (18th December 2021)

8. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Issue 8 (August 2022)

9. The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. Issue 10 (22nd June 2018)